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Abstract
Human metapneumovirus (hMPV) is associated with acute respiratory tract infections, mainly in paediatric patients. The aim of this
study was to evaluate the usefulness of two new commercial techniques available for the detection of hMPV in clinical samples from
children: an enzyme immunoassay, hMPV EIA (Biotrin International Ltd), and a molecular assay, real-time RT-PCR (Pro hMPV Real Time
Assay Kit; Prodesse). A total of 184 nasopharyngeal aspirate specimens from 173 children aged less than 5 years who were hospitalized
with acute wheezing were analysed. Respiratory syncytial virus was detected in 27% of the samples, followed by inﬂuenza A virus (6%),
parainﬂuenza virus (PIV)3 (2.2%), adenovirus (2%), PIV1 (1.1%), PIV2 (1.1%), and inﬂuenza B virus (0.5%). The presence of hMPV was
tested in all samples, using the real-time RT-PCR and EIA. Real-time RT-PCR detected 13 hMPV-positive samples (8%), and EIA
detected 17 (9.3%). When the EIA results were compared with those of real-time RT-PCR for the detection of hMPV, a good correla-
tion was found (94%). A relatively low co-infection rate (15%) was observed in our patients. RT-PCR and EIA provide robust methods
for the diagnosis of hMPV infection in children.
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Introduction
Human metapneumovirus (hMPV) is an RNA virus that was
isolated in 2001 from children with respiratory tract infec-
tions [1]. Two major lineages of hMPV have been identiﬁed,
A and B, with sublineages A1 and A2, and B1 and B2 [2–5].
After the initial report, this virus has been identiﬁed as a
respiratory virus worldwide [4,6–9].
Its clinical manifestations resemble those of respiratory
syncytial virus (RSV), and it is therefore difﬁcult to clinically
distinguish one virus from another. hMPV is a signiﬁcant
cause of acute respiratory disease in children. The most fre-
quent diagnoses in hospitalized children are bronchiolitis and
pneumonia, which occasionally require treatment in inten-
sive-care units [10,11]. hMPV is also a cause of acute respira-
tory disease in adults, particularly the elderly and those with
comorbid conditions such as chronic obstructive pulmonary
disease, asthma, and cancer [12].
Serological studies of stored serum specimens suggested
that hMPV has been circulating in the human population for
more than 50 years [1]. By the age of 5 years, more than
90% of children have serological evidence of hMPV infection
[1,7,13].
Rapid and reliable methods for hMPV detection in clinical
samples are essential for the implementation of appropriate
care, and to obtain a better understanding of the pathology
of hMPV and to determine its epidemiology.
Evaluation of several cell lines for culturing of hMPV has
demonstrated poor applicability for timely detection of the
pathogen in a clinical setting, because the cytopathic effect is
slower and resembles that caused by RSV [14,15]. Immuno-
ﬂuorescence (IF) provides great sensitivity and speciﬁcity as
compared with RT-PCR [16]. Although IF is a simple
method, it has two disadvantages. First, experience is
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required to read the samples; and second, the protocols are
not correctly standardized.
The aim of this study was to evaluate two new techniques
that are commercially available for the detection of hMPV in
clinical samples from children: an enzyme immunoassay,
hMPV EIA (Biotrin International Ltd, Dublin, Ireland), and a
molecular assay, real-time RT-PCR (Pro hMPV Real Time
Assay Kit; Prodesse Inc., Waukesha, WI, USA).
Materials and Methods
Patients and samples
From October 2006 to October 2007, a total of 184 naso-
pharyngeal aspirate specimens were collected from 173 chil-
dren less than 5 years old who were hospitalized with acute
wheezing. A single sample was taken from each patient in
each episode. Aliquots of each sample were stored at )20C
until being tested. Clinical and epidemiological data of
patients were recorded. Episodes in the same patient were
only considered to be new if they occured at least 10 days
after the ﬁrst one. Children with cystic ﬁbrosis or any
known immunodeﬁciency, as well as all those with a bacterial
respiratory tract infection, were excluded. Disease severity
was determined by the number of hospitalization days and
the requirement for oxygen supplementation during the
hospitalization.
Informed consent was obtained from the patients’ parents.
The Ethical Committees of the Hospital Universitari Germans
Trias i Pujol approved the study protocol.
Virus detection
Diagnosis of respiratory virus infection other than by hMPV. An
immunochromatographic assay (Binax Now, Portland, ME,
USA) was used for RSV and inﬂuenza A and B virus detec-
tion, and an indirect IF method (Chemicon International,
Temecula, CA, USA) was used to detect RSV, inﬂuenza A
and B virus, parainﬂuenza virus (PIV)1–3, and adenovirus.
The techniques were applied according to the manufacturers’
recommendations.
hMPV real-time RT-PCR. RNA was extracted using the QIA-
amp Viral RNA kit (Qiagen, Hilden, Germany), following the
manufacturer’s instructions. RNA of hMPV was identiﬁed
using the Pro hMPV Real Time Assay Kit. This assay is a
one-step RT-PCR assay based on nucleic acid extraction,
reverse transcription to generate cDNA from target RNA,
and ampliﬁcation and detection of target cDNA by using a
speciﬁc primer set and probe for a conserved region encod-
ing part of the hMPV nucleocapsid protein.
A single primer set and probe designed by the manufac-
turer, speciﬁc for a highly conserved region of the nucleo-
capsid gene in all four lineages of hMPV, was used.
In brief, reverse transcription and real-time RT-PCR were
performed on extracted nucleic acids using a reaction mixture
containing buffer, MgCl2, dNTPs, oligonucleotide primers,
oligonucleotide probes labelled with ﬂuorescent and quencher
dyes, Platinum Taq DNA Polymerase (Invitrogen, Carlsbad,
CA, USA), and murine leukaemia virus reverse transcriptase
(Applied Biosystems, Foster City, CA, USA). An internal RNA
control was incorporated into every specimen before the
nucleic acid extraction for veriﬁcation of successful extraction,
reverse transcription and PCR in each sample (the technique
was performed once per sample). The internal control was a
non-infectious RNA transcript that is distinguished from the
viral targets of the assay by means of a unique probe-binding
region. If this control is not ampliﬁed, the reaction is
considered to be inhibited. RT-PCR was performed using the
Smart Cycler II system (Cepheid, Sunnyvale, CA, USA). For
more details, the manufacturer should be consulted.
hMPV EIA. The Biotrin hMPV EIA is an antigen capture assay.
Each EIA well is coated with a unique combination of mono-
clonal antibodies recognizing the fusion and matrix proteins
of the virus.
The assay detects all four subgroups of hMPV. The EIA
was performed according to the manufacturer’s instructions.
In short, 165 lL of sample was mixed with 55 lL of extrac-
tion buffer immediately before being added to duplicate
wells.
After a wash step, the anti-hMPV monoclonal antibody–
horseradish peroxidase conjugates were incubated on the
plate. A substrate was then added. When the reaction
stopped, the signal was measured at an absorbance of
450 nm. The cut-off for the assay was determined by adding
the mean optical density of the assay negative control and
adding a constant of 0.10. The cut-off value for each sample
was measured by dividing the mean specimen cut-off by the
negative control cut-off. According to the index obtained,
the result was considered to be negative (<0.9), equivocal
(‡0.9 to £1.1), or positive (>1.1).
Statistical analyses
Cohen’s kappa (j) index was used to determine the concor-
dance between the two techniques. Criteria based on the
interpretation of Landis and Koch [17] were used: kappa val-
ues below 0.4 indicate weak correlation, values of 0.4–0.6
good correlation, and values above 0.6 strong correlation.
All analyses were performed using the Stata 8.0 program
(Stata Corp., College Station, TX, USA).
1664 Clinical Microbiology and Infection, Volume 16 Number 11, November 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1663–1668
For continuous variables, tables of frequency based on
likelihood ratio chi-square were used. The Mann–Whitney
U-test was used to compare the length of hospitalization
between groups; p <0.05 was considered to be signiﬁcant.
Results
Comparison of results obtained with hMPV real-time RT-
PCR and hMPV EIA
Valid results were obtained for 162 nasopharyngeal aspirates
(88%) with the real-time RT-PCR technique. The 22 remain-
ing real-time RT-PCR test samples (12%) were inhibited.
Real-time RT-PCR detected 13 positive samples (8%). In
turn, EIA detected 17 positive samples (9.3%), and only one
sample (0.5%) was equivocal.
RSV was detected in a total of 50 cases (27%), followed
by inﬂuenza A virus in 11 (6%), PIV3 in four (2.2%), adenovi-
rus in three (2%), PIV1 in two (1.1%), PIV2 in two (1.1%),
and inﬂuenza B virus in one (0.5%). No samples that were
hMPV-positive by both techniques were positive for other
viruses, including RSV. Only one real-time RT-PCR-positive
sample was positive for RSV. Two EIA hMPV-positive/hMPV
real-time RT-PCR-negative samples were co-infected with
inﬂuenza A virus.
In order to evaluate the agreement between EIA and real-
time RT-PCR results, the equivocal EIA results and those
of inhibited real-time RT-PCR were not included in the
calculations.
This resulted in 162 samples being used for the calcula-
tions. Ultimately, for samples that could be categorized using
both methods, we found a concordance of 94% (152/162)
(j = 0.633 (standard error: 0.101)). Ten specimens (6%)
(Table 1) were found to be positive with both assays. Dis-
cordant results between EIA and real-time RT-PCR were
found in another ten specimens. Of these, three (2%) were
real-time RT-PCR-positive but antigen-negative, and seven
(4.3%) were antigen-positive but real-time RT-PCR-negative.
Correlation with clinical data
The spectrum of disease severity caused by hMPV is similar
to that of RSV [1,18]. In our children, hMPV-infected chil-
dren were older than RSV-infected children
(9.2 ± 8.1 months vs. 6.3 ± 7.3 months), with statistically sig-
niﬁcant differences (p 0.042), but we found no other signiﬁ-
cant differences regarding the severity of symptoms, with
similar levels of fever (38.6 ± 0.86C vs. 38.2 ± 1.0C), simi-
lar analytical values (leukocytosis, 12 350 vs. 11 900; C-reac-
tive protein levels, 27 mg/L vs. 33.4 mg/L; and procalcitonin
levels, 0.63 ng/mL vs. 0.52 ng/mL), and similar days of hospi-
talization and oxygen therapy (5 and 2 days in the two
groups, respectively).
However, there are clear differences in their seasonal dis-
tribution. RSV cases were detected only between November
and March, with 86% of cases occurring between November
and January, whereas we detected cases of hMPV infection
between September and May, without a clear predominance
of any particular month (Fig. 1).
To analyse the results in terms of hMPV detection, and in
order to avoid bias in the results, the patients with RSV
TABLE 1. Comparison of real-time RT-PCR and Biotrin EIA
results for human metapneumovirus detection in nasopha-
ryngeal aspirates
Real-time RT-PCR, n (%)
Positive Negative Total
EIA Positive 10 (6.1) 7 (4.3) 17 (10.4)
Negative 3 (1.9) 142 (8.7) 145 (89.6)
Total 13 (8.0) 149 (92.0) 162 (100)
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FIG. 1. Seasonality of human metapneu-
movirus (hMPV) and respiratory syncy-
tial virus (RSV) infection from October
2006 to October 2007.
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infection were excluded. If a true hMPV infection was con-
sidered to be an infection in which a sample was positive by
both techniques (real-time RT-PCR and EIA), the children
with hMPV infection required oxygenotherapy more fre-
quently than children who were not infected with hMPV
(p 0.001). In contrast, there was no difference between chil-
dren with and without hMPV in terms of days of hospitaliza-
tion (p 0.288).
If samples that that were hMPV-positive only by real-time
RT-PCR were considered, children with hMPV infection
required oxygenotherapy more frequently than children who
were not infected with hMPV (p 0.005). There was no differ-
ence in days of hospitalization (p 0.059). On the other hand,
if samples that were hMPV-positive only by EIA were consid-
ered, there were no signiﬁcant differences in oxygenotherapy
(p 0.061) or in hospitalization days (p 0.356). There were
also no signiﬁcant differences (oxygenotherapy, p 0.115; days
of hospitalization, p 0.106) between samples that were posi-
tive by at least one of the two techniques.
Discussion
Acute respiratory tract infections are important causes of
morbidity and mortality in children. hMPV is an emerging
pathogen that has been associated with symptoms ranging
from mild upper respiratory tract infections to severe pneu-
monia, exacerbation of asthma, and chronic obstructive pul-
monary disease [3,19–22].
hMPV was not isolated until recently, because ofthe difﬁ-
culty in growing in traditional cell cultures, although it shows
slow growth in the rhesus monkey kidney (LLC-MK2) cell
line [14]. The hMPV assays described by van den Hoogen
et al. have been used in several other studies [6,23]. In all
these studies, RT-PCR was performed with detection by
agarose gel electrophoresis followed by sequencing or
hybridization to conﬁrm an hMPV-positive sample. Currently,
only a few studies have been performed using commercial
assays.
We evaluated two new commercial assays for hMPV
detection, a real-time RT-PCR and an EIA. hMPV was
detected in 8% of the cases with the real-time RT-PCR, and
in 9.3% of the cases with the EIA. The range of incidences
observed in the present study (8–9.3%) is in accordance with
the range of 5–10% observed among hospitalized infants with
acute respiratory tract infections in Spain [24] and other
countries [4,25,26].
A previous study in Catalonia [27] found an hMPV infec-
tion rate of 25%. However, in this study, the rate reﬂects
only the ﬁrst half of the year, corresponding to the peak
infection period, thus increasing the proportion of hMPV
cases.
The comparison of hMPV EIA results with those of real-
time RT-PCR in the detection of hMPV indicates a good cor-
relation between the techniques (94%).
A previous evaluation of hMPV EIA [28] found that the
sensitivity of hMPV EIA sensitivity was lower than that of an
‘in-house’ RT-PCR. However, the majority of hMPV EIA-neg-
ative and RT-PCR/cell culture-positive samples had been fro-
zen for at least 4 years, and this may have led to antigen
degradation and could potentially have affected antigen
detection. In our study, three samples were hMPV real-time
RT-PCR-positive but EIA-negative. It is possible that a low
viral load in these samples might limit detection by EIA, as
has been reported by Kukavica-Ibrulj et al. [28]. On the
other hand, six samples were hMPV-positive only by EIA. It
cannot be excluded that the RNA could have been degraded
in frozen samples, thereby diminishing the yield. One of
these hMPV EIA-positive samples had blood contamination.
The manufacturer has indicated that the presence of blood
in the sample may have led to false-positive results. The
genotype of hMPV may change in consecutive respiratory
tract virus seasons. Recently, Huck et al. [29] described a
novel hMPV sublineage within the A2 group, which they
divided into A2a and A2b. It is possible that hMPV EIA
detects a higher proportion of these sublineages. On the
other hand, PCR methods have inherently greater sensitivity
than the analytical immune-based methods. As the manufac-
turer indicates, the limit of detection, expressed as a median
tissue culture infective dose (TCID), of hMPV real-time RT-
PCR is 101–102 TCID50/mL, and that of hMPV EIA is
104 TCID50/mL. For this reason, we cannot rule out the pos-
sibility that hMPV EIA-positive and real-time RT-PCR-nega-
tive samples are false positives. Interestingly, none of the
patients with samples positive only by EIA required supple-
mental oxygen, as compared with the majority of children
who were hMPV-positive by both techniques. Further investi-
gations are required.
In our experience, hMPV was involved in severe respira-
tory infections that required oxygen treatment, although
there were no deaths. Our results showed that oxygen
treatment was necessary in 35% of all cases. This percentage
is lower than that previously reported by Mullins et al. [30]
(54%) and do Carmo et al. [26] (70%), who analysed a similar
population. Given the low number of positive samples, the
percentage of children with oxygen treatment might have
been underestimated. However, children with hMPV-positive
samples by both real-time RT-PCR and EIA required oxy-
genotherapy more frequently than children who were not
infected with hMPV (p 0.005).
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The detection of viruses in nasopharyngeal aspirates pro-
vides only indirect evidence of the aetiology of respiratory
infection. Viral quantiﬁcation and serial monitoring contribute
to the management and diagnosis of viral infections. How-
ever, in our experience, in agreement with previous reports,
hMPV is not frequently detected in samples from healthy
children (unpublished data). The fact that hMPV is commonly
found in association with respiratory illness, but not in
asymptomatic children and adults, supports its role as a true
pathogen [22,31].
Previous studies have suggested that dual infection with
hMPV and other respiratory viruses is frequent [24,32].
Moreover, other studies have indicated that co-infection with
RSV is more severe than hMPV or RSV infection alone
[4,32]. However, a relatively low co-infection rate was found
in our patients. Other respiratory viruses were detected in
three (15%) hMPV-positive samples, and only one of these
co-infections involved RSV.
Because the different methods used for detecting a wide
range of respiratory viruses have various sensitivity rates, the
exact contribution of each virus to respiratory tract disease
remains difﬁcult to assess. Nevertheless, our results, in
agreement with previous reports, indicate that RSV is the
most common virus, in that it causes lung and airway infec-
tions in infants and young children.
Moreover, hMPV infection was more common than ade-
novirus, inﬂuenza virus and PIV infections. This study, in
agreement with previous studies [4,33], has demonstrated
the prevalence of major respiratory viruses that cause infec-
tions in hospitalized children.
The main limitation of our study is the lack of a reference
method (viral culture) for better analysis of the discordant
results obtained with RT-PCR and EIA. Despite this limita-
tion, our study provides relevant data related to the clinical
utility of the tests evaluated for the detection of hMPV in
clinical samples.
Molecular methods have been considered to be the refer-
ence standard methods for hMPV detection, in light of the
slow replication of this virus in viral culture. However, cul-
ture-based methods require expensive laboratory equipment
and carefully trained personnel.
The EIA technique is a more rapid, less expensive and
highly speciﬁc method for detection of hMPV in clinical sam-
ples, and it can be used in microbiology laboratories without
a molecular platform. The Biotrin hMPV EIA is a convenient
alternative to PCR for the detection of hMPV with excellent
speciﬁcity.
In our experience, real-time RT-PCR and EIA are a good
alternative methods for the diagnosis of hMPV infection. Our
results, in agreement with previous reports, indicate that
hMPV is one of the leading causes of lower respiratory tract
infections in young children. The inclusion of new techniques
for hMPV detection increased the percentage of diagnosis
from 36% to 42%, allowing an aetiological diagnosis in 17%
of the cases that are negative for other viruses.
With hMPV detection in microbiology laboratories, testing
can improve the aetiological diagnosis of acute respiratory
infections in children.
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